“Commentary on ‘Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicenter, open-label, randomized controlled trial’” (2024) Bleeding, Thrombosis and Vascular Biology, 3(2). doi:10.4081/btvb.2024.141.